Lorlatinib
Brand name: Lorbrena
Rank #481 of 500 drugs by total cost
$14.7M
Total Cost
720
Total Claims
$14.7M
Total Cost
51
Prescribers
$20K
Cost per Claim
0
Beneficiaries
722
30-Day Fills
$287K
Avg Cost/Provider
14
Avg Claims/Provider
About Lorlatinib
Lorlatinib (sold as Lorbrena) was prescribed 720 times by 51 Medicare Part D providers in 2023, costing the program $14.7M. At $20K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 478 | Raloxifene Hcl (Raloxifene Hcl) | $14.8M | 198,063 |
| 479 | Lanthanum Carbonate (Lanthanum Carbonate) | $14.7M | 13,783 |
| 480 | Mometasone Furoate (Mometasone Furoate) | $14.7M | 266,966 |
| 481 | Lorlatinib (Lorbrena) | $14.7M | 720 |
| 482 | Rasagiline Mesylate (Rasagiline Mesylate) | $14.5M | 47,985 |
| 483 | Pazopanib Hcl (Votrient) | $14.5M | 1,156 |
| 484 | Exemestane (Exemestane) | $14.5M | 66,285 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology